Statistics

Total Visits

Views
FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial111

File Visits

Downloads
VERSION EDITOR.pdf24

Select a period of time:

Number of views in the range

Views
FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial33

Number of downloads in the range

Downloads
VERSION EDITOR.pdf11

Views

Views
September 20255
October 20251
November 20255
December 20257
January 202614
February 20261
March 20260
Download CSV file
 untranslated
 untranslated

Number of downloads in the period of time

  • Downloads
  • September 2025
    2
  • October 2025
    0
  • November 2025
    0
  • December 2025
    4
  • January 2026
    3
  • February 2026
    1
  • March 2026
    1
  • Download CSV file
 untranslated
 untranslated

Top country views

Views
United States18
Ecuador2
United Kingdom2
Uruguay2
Brazil2
Argentina1
Bangladesh1
Bolivia1
Canada1
Panama1
 

Top countries by downloads

Downloads
United States9
United Kingdom1
 

Top cities views

Views
San Jose7
Ashburn7
Montevideo2
Chino Valley1
Cochabamba1
Johannesburg1
Lima1
Los Angeles1
Panama City1
Portland1
 

Top cities by downloads

Downloads
Ashburn1
Los Angeles1